BioMarin disclosed an additional enzyme-replacement buy, paying $70 million for a long-acting Fabry program that it says could expand access beyond patients eligible for Amicus Therapeutics’ earlier Fabry therapy. The deal adds a clinical-stage asset with an explicit rationale: potentially lower dosing burden versus existing options. The transaction also signals continued investor focus on lysosomal storage disease franchises where longer-interval dosing is becoming a core competitive differentiator. BioMarin framed the move as a way to broaden the treating population and capture incremental value through improved convenience. While the underlying clinical dataset details were not included in the provided brief, the timing—after BioMarin’s Amicus acquisition earlier in the year—places Fabry as a near-term growth lever within the company’s broader enzyme replacement footprint.